Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2026-03-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药第三届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's third board meeting, including approvals of various reports and proposals such as the 2025 annual board work report, president's work report, independent directors' reports, audit committee reports, annual report, profit distribution plan, appointment of audit institutions, remuneration plans, internal control evaluation, ESG report, fundraising usage report, and other governance and operational matters. It also mentions that many of these reports are disclosed separately on the stock exchange website and that some proposals require shareholder approval. The document is not the reports themselves but a formal announcement of board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document is over 5,000 characters and contains substantive content about board resolutions, not just a brief notice or certification. Therefore, the correct classification is MANG with high confidence.
2026-03-27 Chinese
国邦医药2025年度独立董事述职报告（左卫民）
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings, committee participation, communication with shareholders, and oversight activities. It does not contain financial statements or audit results, nor is it a transcript or announcement. It is a management-related report focusing on the independent director's role and activities, which fits best under Board/Management Information (MANG). The document length is under 5,000 characters but it is a substantive report, not a mere announcement or certification. Therefore, the classification is MANG with high confidence.
2026-03-27 Chinese
立信会计师事务所关于国邦医药2025年度审计报告及财务报表
Regulatory Filings
2026-03-27 Chinese
国邦医药2025年度独立董事述职报告（吴晓明-已离任）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 of Guobang Pharmaceutical Group Co., Ltd. It details the independent director's duties, attendance at meetings, supervision activities, communication with shareholders, and evaluation of company governance and financial reporting. The content focuses on the independent director's role and performance rather than presenting financial statements or audit results. It is a formal report on the independent director's work and responsibilities during the fiscal year, which aligns with a Management Reports category rather than an Annual Report or Audit Report. There is no indication that this is a full annual report or audit report, nor is it a brief announcement or certification. Therefore, the document fits best under the Management Reports (MDA) category.
2026-03-27 Chinese
国邦医药2025年度独立董事述职报告（张晟杰-已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 of Guobang Pharmaceutical Group Co., Ltd. It details the independent director's duties, attendance at meetings, supervision activities, communication with shareholders, and evaluation of company governance and financial reporting. The content focuses on the independent director's role and performance rather than presenting financial statements or audit results. It is a formal report on the independent director's work and oversight during the fiscal year, which is a type of management or governance report. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is also not a simple announcement or certification. Given the nature of the document, it fits best under Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities, including independent directors' reports.
2026-03-27 Chinese
国邦医药对会计师事务所2025年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (立信会计师事务所) for the year 2025, specifically regarding their audit services for 国邦医药集团股份有限公司. It details the auditor's qualifications, independence, audit procedures, quality control, and risk management related to the audit engagement. It does not contain the actual audited financial statements or the full annual report but rather assesses the auditor's performance and compliance with regulatory requirements. This type of document is a standalone audit-related report focusing on the auditor's work and internal controls, fitting the category of Audit Report / Information (AR). The document length is about 4511 characters, which is sufficient for a detailed audit evaluation report, not a brief announcement or certification. Therefore, the correct classification is AR with high confidence.
2026-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.